Trial · NCT06412497
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
NCT06412497, Phase 2, Recruiting, Masonic Cancer Center, University of Minnesota
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure. Trials, record NCT06412497. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06412497
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- NCT number
- NCT06412497
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
- First posted
- 2024-05-14
- Last updated
- 2026-06-03
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of grade 3-4 acute GvHD | 1 year post HCT | Incidence of grade 3-4 acute graft-versus host disease (GvHD) at 1 year post HCT. |
| Primary | Incidence of chronic GvHD-free, failure-free survival (GFFS) | 1 year post HCT | Incidence of chronic GvHD-free, failure-free survival (GFFS) 1 year post HCT |
| Primary | Incidence of chronic GvHD-free survival | 1 year post HCT | Incidence of chronic GvHD-free survival at 1 year post HCT |
| Secondary | Incidence of failure-free survival (GFFS) | 2 years post HCT | Incidence of chronic GvHD-free, failure-free survival (GFFS) 2 years post HC |
| Secondary | Incidence of neutrophil recovery | Day 42 post HCT | Incidence of neutrophil recovery at day 42 post HCT |
| Secondary | Incidence of platelet recovery | 6 months post HCT | Incidence of platelet recovery at 6 months post HCT |
| Secondary | Incidence of grade 3-4 acute GvHD | 100 days post HCT | Incidence of grade 3-4 acute GvHD at 100 days post HCT |
| Secondary | Incidence of any chronic GvHD | 1 year post HCT | Incidence of any chronic GvHD at 1 year post HCT |
| Secondary | Overall survival | 1 and 2 years post HCT | Overall survival at 1 and 2 years |
| Secondary | Incidence of chronic GvHD-free survival | 2 years post HCT | Incidence of chronic GvHD-free survival at 2 years post HCT |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06412497
GET https://conductscience.org/api/trials/v1/NCT06412497/registered